

Serraquin ES15[®]

Equine

CLINICAL STUDIES

Steel Horse Formulations

85 W Combs Rd San Tan Valley, AZ USA

Phone: 877.378.1178

Email: contact@serraquin.com

EFFICACY OF SERRAQUIN ES15 IN TREATING NON-SPECIFIC CASES OF LAMENESS AMONG EQUINES (In Brief)

Dr. Rakesh Pattu, BVSc & AH

Study on File 9/20/2005

1) A trial was conducted on six race horses suffering from non-specific lameness. The goal of the study was to test the efficacy of SERRAQUIN ES15 in ameliorating their condition. SERRAQUIN ES15 was formulated by Steel Horse Formulations.

2) All six clinically lame horses have been examined and the seat of lameness identified. All horses were given SERRAQUIN ES15 powder at 10 grams orally three times daily for a period of 7 days. No other analgesic, anti-inflammatory or moist dressings were used.

3) Five out of six horses showed complete recovery and one horse continued to show lameness.

The results are as follows:

Number	Name	Diagnosis	Remarks
1	Flying Hawk	Tendinitis LF	Responded
2	Heart Throb	Sprain Ligament Knee LF	No Response
3	Power On	Sprain Ligament Lumbar Region	Responded
4	Answer	Sprain Muscle Should LF	Responded
5	Montgomery Hero	Tendinitis RF	Responded
6	Picardo	Sprain Ligament Stifle RH	Responded

4) Hematological, urine and fecal examination was carried out during pre and post trial period. No significant hematological, urine or fecal parameter changes were noted.

Conclusion:

Since the results are quite encouraging, a comparative study on a larger number of animals to further determine its efficacy on bone, tendon, ligament and muscle related conditions.

Efficacy of ingredients in SERRAQUIN ES15 in Equine Lameness, An Observation (Abstract)

Study on File 4/18/2006

Dr. Surajit Basu BVSC & AH

In a study of a 16 year old gelding and a 7 year old mare, both presenting with lameness, the combination of proteolytic enzymes in SERRAQUIN ES15 demonstrated effectiveness in reducing pain & inflammation. In addition, the product demonstrates fibrinolytic activity and improves microcirculation to the affected areas.